Depomed Inc

Depomed — Proxy Contest (October 2015)

29 slides from Depomed's proxy contest presentation, Oct 19, 2015

  1. Slide 1: Forward-Looking Statements

    Forward-Looking Statements The statements that are not historical facts contained in this presentation are forward-looking statements that involve risks and uncertainties including, but not limited to, those related to Depomed’s acquisition of the NUCYNTA® franchise in the United States, Depomed’s p

  2. Slide 2: Depomed – A Force in Pain and Neurology, in a Period of Accelerated Growth

    October 2015 Depomed – A Force in Pain and Neurology, in a Period of Accelerated Growth Strong Product Portfolio Marketing six branded, differentiated products in pain and neurology with lengthy exclusivity (1) Track Record of Accelerated Growth Organic growth - success increasing product sales, scr

  3. Slide 3: Depomed's Track Record of Successful Deals Builds Value

    Reworked Santarus deal and tripled net revenue 47% revenue growth Q2 2015 over Q2 2014 Acquired Dec 2013; relaunched Q1 2014; 35% increase in demand Q2 2015 over Q2 2014 Q3 2011 Q4 2011 Q4 2013 TYPE 2 DIABETES DEAL Non-strategic milestones & royalties sold for $240 million Q4 2013 Relaunch Q4 2013 f

  4. Slide 4: Depomed's "Acquire, Integrate, Grow" Business Model Driving An Accelerated Growth Cycle

    Depomed’s “Acquire, Integrate, Grow” Business Model Driving An Accelerated Growth Cycle 5 October 2015 ACQUIRE Pain and neurology products with lengthy exclusivity and peak sales ahead INTEGRATE Speed and efficiency from playbook based on past success with same team GROW Repositioning and marketing

  5. Slide 5: Execution of Business Model Driving Triple Digit Growth in Sales and Significant Profitability

    Depomed’s Execution of Business Model Driving Triple Digit Growth in Sales and Significant Profitability $500K $27.1M $58.1M $114M $320M-340M (1) October 2015 2015 Total Product Sales Guidance (Includes NUCYNTA starting April 2, 2015) Adjusted EBITDA (Midpoint of adjusted EBITDA Guidance) $102.5M At

  6. Slide 6: Execution of Business Model Driving Sales Growth, Rx Growth, Market Share

    Depomed - Execution of Business Model Driving Sales Growth, Rx Growth, Market Share October 2015 Product Sales Growth (Y/Y) Prescription Growth (Y/Y) Market Share Growth (Q/Q) 38% growth 2Q15: $20.9M 18% growth 2Q15: 83k 2Q15: 3.2% share 2Q14: 2.8% share 36% growth 2Q15: $6.8M 35% growth 2Q15: 35k 2

  7. Slide 7: Depomed's Clear Track Record of Value Creation

    Depomed’s Clear Track Record of Value Creation 8 October 2015 Depomed is in a Period of Significant Growth and We Believe is Well-Positioned for Future Success Source: Stock chart from BigCharts.com Covering 9/30/10 to 9/30/15. Includes period following Horizon’s initial public offer. Depomed does n

  8. Slide 8: Depomed 2Q 2015 - Continued Strong Performance With Record Sales and Cash Flow

    Depomed 2Q 2015 - Continued Strong Performance With Record Sales and Cash Flow - Revenue Up 234% Over Prior Year 9 October 2015 Record Quarterly Results 2015 Guidance Updated* Additional Highlights Net product sales of $94.3M (234% over Q2 2014) Added $55M of cash in second quarter Product sales rai

  9. Slide 9: Depomed Expected to be a Top 5 Branded Pain Company by 2016

    10 10 October 2015 Acute Pain Breakthrough Cancer Pain Chronic Pain Neuropathic Pain Migraine ü ü ü ü ü ü ü ü ü ü ü ü ü ü Source: Depomed Marketing, company websites Depomed Expected to be a Top 5 Branded Pain Company by 2016 ü We Believe Depomed is Building the Most Complete Pain Portfolio in the I

  10. Slide 10: NUCYNTA Leading The Latest Chapter of Depomed's Growth Story

    NUCYNTA Leading The Latest Chapter of Depomed’s Growth Story – Blockbuster Potential (1) Adds significant revenue and earnings to an already strong business Only new chemical entity in CII space approved by FDA in last 30 years Competes in multi-billion dollar pain market Exclusivity expected for a

  11. Slide 11: Depomed's NUCYNTA Growth Strategy – Targeting to Surpass $1 Billion in Sales

    Depomed’s NUCYNTA Growth Strategy – Targeting to Surpass $1 Billion in Sales (1) October 2015 Proper Dosing Pricing and Access Positioning Promotion Significantly increased promotion and marketing efforts Revamped product positioning and messaging Maximize brand through pricing and access strategies

  12. Slide 12: Promotion: Significantly Increased to Drive Prescriptions and Market Share

    Promotion: Significantly Increased to Drive Prescriptions and Market Share 13 October 2015 Increased Sales Force 1 Optimized Medical Education Identifying Appropriate Target Prescribers Promotion strategy consists of: 3-fold increase to 275 reps Highly experienced in pain and neurology Resumed full

  13. Slide 13: Promotion Progress: Accelerating Demand - Rx Growth of 14.2% Over Prior Year

    Sales force delivering approximately 10k NUCYNTA calls per week since re-launch PAINWeek® 2015 1,000+ attendees at NUCYNTA and CME-sponsored symposia Speaker Program Education: early focus and success 710 attendees on 7/30 national webcast; >200 high decile targets 650+ programs targeted for 2015 Ye

  14. Slide 14: Positioning: Only FDA Approved Product that Addresses Both Nociceptive and Neuropathic Pain

    Positioning: Only FDA Approved Product that Addresses Both Nociceptive and Neuropathic Pain 15 October 2015 Chronic pain affects 1/3 of the US population More than 100 million adults with chronic pain 31 million with chronic lower back pain (CLBP) Potential significant impact from even modest uptick

  15. Slide 15: Positioning Progress: Market Share Increased From 1.49% to 1.65% Since Re-Launch

    Competes in >$5 billion dollar Long Acting Opioid (LAO) market Increased promotional activities with new messaging resonating with prescribers Key opinion leaders educating on potential dual mechanism and titration Market share of LAO market now 1.65%, up from 1.49% from immediately before re-launch

  16. Slide 16: Pricing and Access: Maximizing Brand Through Pricing and Access Strategies

    Pricing and Access: Maximizing Brand Through Pricing and Access Strategies 17 October 2015 94% of commercial lives have access to NUCYNTA and NUCYNTA ER United Healthcare Commercial moved NUCYNTA ER in front of Oxycontin on formulary as of July 1, 2015 Oxycontin removed from Tier 2 and now requires

  17. Slide 17: Proper Dosing: Education on Titration is Key

    Proper Dosing: Education on Titration is Key Average dose in low back pain trials was ~400mg/day after titration 18 October 2015 4 200 mg Proper Dose May Improve Physician and Patient Experience as well as Increase Average Selling Price Expert Opin. Pharmacother. (2010) 11(11):1787-1804 250 mg ~400

  18. Slide 18: NUCYNTA Patent Protection Expected to Provide Market Exclusivity for a Decade or More

    NUCYNTA Patent Protection Expected to Provide Market Exclusivity for a Decade or More (1) October 2015 NUCYNTA >$500MM by 2020 and $1 Billion Before Patent Expiry (2) February 2023: Expiry of patents covering tapentadol (composition of matter plus pediatric extension) December 2025: Expiry of polymo

  19. Slide 19: Depomed's Highly Differentiated Growing Portfolio of Assets in Addition to NUCYNTA

    October 2015 Depomed’s Highly Differentiated Growing Portfolio of Assets in Addition to NUCYNTA Product Differentiation 2Q Annualized Revenues Growth Over 1Q 2015 Expected Exclusivity (1) 1x daily with less dizziness and somnolence $84M 21% April 2015 ANDA settlement provides exclusivity to 2024 Onl

  20. Slide 20: Depomed Sales Force Effectively Targets Key Specialties

    Depomed Sales Force Effectively Targets Key Specialties Core Sales Force n=275 Cancer Pain Specialists n=24 Pain Focused Neurology Focused 21 October 2015

  21. Slide 21: Depomed's Ability to Efficiently Execute and Deliver Growth - Gralise

    October 2015 Depomed’s Ability to Efficiently Execute and Deliver Growth - Gralise Reacquired marketing rights March 2011 and received $40M payment Launched in October 2011 >$84 million run rate as of Q2 2015 Tier 2 coverage at the three largest pharmacy benefit managers, CVS/Caremark, ESI, Catamara

  22. Slide 22: Depomed's Ability to Efficiently Execute and Deliver Growth - CAMBIA

    October 2015 Depomed’s Ability to Efficiently Execute and Deliver Growth - CAMBIA Acquired in December 2013 for $48.7M Relaunched in February 2014 $27 million run rate as of Q2 2015 Only single agent in its therapeutic class approved in the U.S. for treatment of acute migraine attacks in adults Excl

  23. Slide 23: Depomed's Ability to Efficiently Execute and Deliver Growth - Lazanda

    October 2015 Depomed’s Ability to Efficiently Execute and Deliver Growth - Lazanda Acquired in July 2013 for $4M Relaunched in October 2013 $15.4 million run rate as of Q2 2015 Market share has doubled in last 12 months and 4x since relaunch Effective January 1st, only branded rapid acting fentanyl

  24. Slide 24: Lengthy Exclusivity Periods Mean Products Contributing to Revenue Growth for a Long Time

    Lengthy Exclusivity Periods Mean Products Contributing to Revenue Growth for a Long Time October 2015 Securing Market Exclusivity for Depomed Products Well Into Next Decade (1) Product Expected Exclusivity 2028 Acquired April 2015; composition of matter patent to 2022/2023; polymorph and method of t

  25. Slide 25: Acquire, Integrate, and Grow Strategy Will Continue to Create Value

    October 2015 We Expect Depomed’s Acquire, Integrate, and Grow Strategy will Continue to Create Value Maintain pain and neurology focus, leveraging management’s expertise Products with current annual revenue between $20-$200MM+ Targeting products with lengthy exclusivity and future peak sales Rapid D

  26. Slide 26: Collaborations and Intellectual Property Provide Revenue Upside Over the Next Decade

    Depomed’s Collaborations and Intellectual Property Provide Revenue Upside Over the Next Decade IP Litigation Potential future cash flow from IP litigation against Purdue Pharma and Endo PTAB has confirmed the patentability of each of the 25 claims subject to Purdue IPRs, the patentability of each of

  27. Slide 27: Depomed – A Force in Pain and Neurology, in a Period of Accelerated Growth

    October 2015 Depomed – A Force in Pain and Neurology, in a Period of Accelerated Growth Strong Product Portfolio Marketing six branded, differentiated products in pain and neurology with lengthy exclusivity (1) Track Record of Accelerated Growth Organic growth - success increasing product sales, scr

  28. Slide 28: Depomed — A Force in Pain and Neurology, in a Period of Accelerated Growth

    Depomed —A Force in Pain and Neurology, in a Period of Accelerated Growth Seeders © Marketing six branded, differentiated products in pain and neurology with lengthy exclusivity (?) ‘ortfolio Track Record of ® Organic growth - success increasing product sales, scripts and market share PERCU © Acquis

  29. Slide 29: Thank You

    pve ans < Depomed Thank You www.depomed.com

Depomed — Proxy Contest (October 2015) on 6ix